Skip to main content
Robert Brink

Professor Robert Brink

Role
Program Director - Immune Biotherapies / Laboratory Head - B Cell Biology
Lab/Group
B Cell Biology Lab

Professor Robert Brink obtained his Honours degree in Science from the University of Sydney in 1987 where he majored in Biochemistry and Genetics. He completed his PhD in 1992 under the supervision of Antony Basten and Chris Goodnow at Sydney’s Centenary Institute, where he worked on novel transgenic mouse models of B cell self-tolerance.

In 1994 he took up a postdoctoral position in the laboratory of Harvey Lodish at the Whitehead Institute in Boston, where he investigated how the newly identified TRAF family of intracellular proteins function in signal transduction by cell membrane receptors. Upon returning to the Centenary Institute in 1996, Robert developed a number of genetically modified mouse models designed to elucidate in vivo B cell responses and TRAF protein function. These models have been successfully employed within his laboratory and in laboratories around the world to make landmark findings published in journals such as Immunity, J. Exp. Med., Cell and Nature Immunology.

In 2006 Robert was recruited to the Garvan Institute of Medical Research in Sydney to head the B Cell Biology laboratory. In 2010, he was appointed Head of the Institute’s Immunology Research Division. He was appointed Conjoint Associate Professor at the University of NSW in 2011 and Conjoint Professor in the Faculty of Medicine 2014. Robert is a Senior Research Fellow of the National Health and Medical Research Council (NHMRC) and member of an NHMRC Program Grant team since 2002. His major research focus is the regulation B cell survival and antibody production during protective immune responses and how these processes contribute to diseases such as autoimmunity, allergy and cancer.

Selected publications

See all publications
  • 2024
    Immunity10.1016/j.immuni.2024.08.017

    Conversion of vaccines from low to high immunogenicity by antibodies with epitope complementarity.

    Alexandra R Dvorscek, Craig I McKenzie, Vera C Stäheli, Zhoujie Ding, Jacqueline White, Stewart A Fabb, Leonard Lim, Kristy O'Donnell, Catherine Pitt, Daniel Christ, Danika L Hill, Colin W Pouton, Deborah L Burnett, Robert Brink, Marcus J Robinson, David M Tarlinton, Isaak Quast
  • 2024
    Science (New York, N.Y.)10.1126/science.add8947

    Germline mutations in a G protein identify signaling cross-talk in T cells.

    Hyoungjun Ham, Huie Jing, Ian T Lamborn, Megan M Kober, Alexey Koval, Yamina A Berchiche, D Eric Anderson, Kirk M Druey, Judith N Mandl, Bertrand Isidor, Carlos R Ferreira, Alexandra F Freeman, Sundar Ganesan, Meliha Karsak, Peter J Mustillo, Juliana Teo, Zarazuela Zolkipli-Cunningham, Nicolas Chatron, François Lecoquierre, Andrew J Oler, Jana Pachlopnik Schmid, Douglas B Kuhns, Xuehua Xu, Fabian Hauck, Waleed Al-Herz, Matias Wagner, Paulien A Terhal, Mari Muurinen, Vincent Barlogis, Phillip Cruz, Jeffrey Danielson, Helen Stewart, Petra Loid, Sebastian Rading, Boris Keren, Rolph Pfundt, Kol A Zarember, Katharina Vill, Lorraine Potocki, Kenneth N Olivier, Gaetan Lesca, Laurence Faivre, Melanie Wong, Anne Puel, Janet Chou, Maud Tusseau, Niki M Moutsopoulos, Helen F Matthews, Cas Simons, Ryan J Taft, Ariane Soldatos, Etienne Masle-Farquhar, Stefania Pittaluga, Robert Brink, Danielle L Fink, Heidi H Kong, Juraj Kabat, Woo Sung Kim, Tatjana Bierhals, Kazuyuki Meguro, Amy P Hsu, Jingwen Gu, Jennifer Stoddard, Benito Banos-Pinero, Maria Slack, Giampaolo Trivellin, Benoît Mazel, Maarja Soomann, Samuel Li, Val J Watts, Constantine A Stratakis, Maria F Rodriguez-Quevedo, Ange-Line Bruel, Marita Lipsanen-Nyman, Paul Saultier, Rashmi Jain, Daphne Lehalle, Daniel Torres, Kathleen E Sullivan, Sébastien Barbarot, Axel Neu, Yannis Duffourd, Morgan Similuk, Kirsty McWalter, Pierre Blanc, Stéphane Bézieau, Tian Jin, Raif S Geha, Jean-Laurent Casanova, Outi M Makitie, Christian Kubisch, Patrick Edery, John Christodoulou, Ronald N Germain, Christopher C Goodnow, Thomas P Sakmar, Daniel D Billadeau, Sébastien Küry, Vladimir L Katanaev, Yu Zhang, Michael J Lenardo, Helen C Su
  • 2024
    Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie10.1016/j.biopha.2024.116730

    The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury.

    Marina Katerelos, Kurt Gleich, Geoff Harley, Kim Loh, Jonathan S Oakhill, Bruce E Kemp, David P de Souza, Vinod K Narayana, Melinda T Coughlan, Adrienne Laskowski, Naomi X Y Ling, Lisa Murray-Segal, Robert Brink, Mardiana Lee, David A Power, Peter F Mount
  • 2024
    Science Translational Medicine10.1126/scitranslmed.adj0133

    Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease.

    Ziyan Pan, Rasha El Sharkway, Ali Bayoumi, Mayada Metwally, Brian S Gloss, Robert Brink, David Bo Lu, Christopher Liddle, Saleh A Alqahtani, Jun Yu, Philip J O'Connell, Jacob George, Mohammed Eslam
  • 2023
    IScience10.1016/j.isci.2023.106477

    β-cell function is regulated by metabolic and epigenetic programming of islet-associated macrophages, involving Axl, Mertk, and TGFβ receptor signaling.

    Le May Thai, Liam O'Reilly, Saskia Reibe-Pal, Nancy Sue, Holly Holliday, Lewin Small, Carsten Schmitz-Peiffer, Rama Dhenni, Vicky Wang-Wei Tsai, Nicholas Norris, Belinda Yau, Xuan Zhang, Kailun Lee, Chenxu Yan, Yan-Chuan Shi, Melkam A Kebede, Robert Brink, Gregory J Cooney, Katharine M Irvine, Samuel N Breit, Tri G Phan, Alexander Swarbrick, Trevor J Biden